Recently Updated Topics on ARUP Consult Can Help Clinicians Identify and Manage Blood Cancers

Blood cancers are some of the most common and dangerous cancers and affect 1.6 million people in the United States. Despite the number of patients diagnosed with blood cancers, awareness is low. September is Blood Cancer Awareness Month, a global event to help raise awareness of blood cancers and their signs and symptoms and improve early diagnosis. ARUP Consult^®, a free source of expert guidance in laboratory testing, has new and updated resources on hematologic malignancies and blood cancers that describe how laboratory tests can be used in the diagnosis, prognosis, treatment, and management of these diseases.

The hematologic malignancies resources include the following ARUP Consult topics: Acute Myeloid Leukemia - AML, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Mast Cell Disorders, Minimal Residual Disease Testing, Chromic Myeloid Leukemia - CML, Acute Lymphoblastic Leukemia - ALL, Chronic Lymphocytic Leukemia - CLL, Plasma Cell Dyscrasias, Eosinophil-Related Disorders - Eosinophilia, Mature B-Cell Lymphomas, and T-Cell and NK-Cell Lymphomas.

These and other offerings, which summarize current clinical practice guidelines, testing strategies, and relevant technical details, are updated regularly and tailored to clinicians to help them choose the right test at the right time.

ARUP medical directors, who are active faculty members at the Spencer Fox Eccles School of Medicine at the University of Utah and its Department of Pathology, review and contribute to the content on ARUP Consult. They are nationally and internationally recognized pathologists, subspecialty-qualified clinicians, and board-certified clinical scientists who make significant contributions in research and development. They also author textbooks and journal articles and present lectures, workshops, and symposia at regional, national, and international meetings.

Read on for more information about recent changes. Subscribe to the ARUP Consult monthly newsletter to have updates and highlights like these delivered directly to your inbox.

Acute Myeloid Leukemia - AML

Acute myeloid leukemias (AMLs) are heterogeneous blood cancers characterized by myeloid blasts (e.g., undifferentiated myeloid precursors) in the blood, bone marrow, and/or other tissues. These conditions include AML with myelodysplasia-related gene mutations (MDS/AML) and acute promyelocytic leukemia (APL). In addition to morphologic evaluation of the bone marrow, immunophenotypic, cytogenetic, and molecular genetic studies are standard of care in AML and are necessary for accurate classification and risk stratification and to guide therapy. Visit the updated ARUP Consult Acute Myeloid Leukemia - AML topic to find Quick Answers for Clinicians and learn more about laboratory testing.

Mast Cell Disorders

Mast cell disorders (MCDs), including mast cell activation syndrome (MCAS) and mastocytosis, are a diverse group of conditions that range in severity from benign disorders to rapidly progressing systemic clonal diseases. The diagnostic approach to MCDs varies based on the type of disorder but often involves laboratory testing. Visit the updated ARUP Consult Mast Cell Disorders topic to learn the latest about the use of serum tryptase testing, KIT mutational analysis, and tryptase genotyping in the evaluation of suspected mastocytosis, and see a revised algorithm that incorporates recent guidance.

Feedback

ARUP welcomes feedback and suggestions via the Feedback page on arupconsult.com.

Additional Resources

Learn more about ARUP’s robust hematopathology testing suite here.

Read how ARUP’s highly sensitive tests help solve diagnostic puzzles for patients with systemic mastocytosis here.

Bonnie Stray, bonnie.stray@aruplab.com